Andy Chen
Stock Analyst at Wolfe Research
(4.64)
# 866
Out of 4,639 analysts
73
Total ratings
70.2%
Success rate
30.1%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Andy Chen
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDGL Madrigal Pharmaceuticals | Upgraded: Buy | $605 | $535.27 | +13.03% | 3 | Aug 4, 2026 | |
| VRTX Vertex Pharmaceuticals | Maintained: Buy | $548 → $557 | $529.65 | +5.16% | 5 | Aug 3, 2026 | |
| SYRE Spyre Therapeutics | Downgraded: Hold | n/a | $102.74 | - | 2 | Jul 28, 2026 | |
| IONS Ionis Pharmaceuticals | Downgraded: Hold | n/a | $55.42 | - | 3 | Jul 15, 2026 | |
| NTLA Intellia Therapeutics | Downgraded: Sell | $9 | $12.02 | -25.12% | 5 | Jul 15, 2026 | |
| SRPT Sarepta Therapeutics | Upgraded: Buy | $27 | $18.22 | +48.19% | 2 | Jul 8, 2026 | |
| CLDX Celldex Therapeutics | Maintained: Buy | $44 | $44.33 | -0.74% | 4 | Jun 14, 2026 | |
| ABVX ABIVAX Société Anonyme | Rated: Buy | $176 → $136 | $126.81 | +7.25% | 2 | Jun 3, 2026 | |
| VERA Vera Therapeutics | Maintained: Buy | $88 | $30.29 | +190.52% | 4 | Jun 2, 2026 | |
| PALI Palisade Bio | Initiated Coverage: Buy | $7 | $2.14 | +227.10% | 1 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $48 | $19.47 | +146.53% | 1 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $98 | $108.49 | -9.67% | 1 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $42 | $34.42 | +22.02% | 1 | Apr 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $47 | $40.93 | +14.83% | 4 | Apr 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | $24 | $16.59 | +44.67% | 5 | Mar 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $134.69 | - | 1 | Jan 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $109.62 | - | 4 | Jan 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | n/a | $864.74 | - | 3 | Nov 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $13 | $4.72 | +175.42% | 1 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $54 → $173 | $132.57 | +30.50% | 3 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | n/a | $221.20 | n/a | 4 | Aug 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $49 | $83.70 | n/a | 1 | Jun 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $25 | $57.87 | n/a | 2 | May 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $84 | $121.07 | n/a | 2 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $20 | $104.68 | n/a | 1 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $84.36 | n/a | 1 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $19 | $32.44 | n/a | 1 | Feb 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Buy | $29 | $22.97 | n/a | 1 | Jun 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Hold | n/a | $54.07 | n/a | 1 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | n/a | $35.25 | n/a | 1 | Feb 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $4 | $7.18 | n/a | 1 | Oct 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $60 | $0.0001 | n/a | 2 | Aug 10, 2023 |
Madrigal Pharmaceuticals
Aug 4, 2026
Upgraded: Buy
Price Target: $605
Current: $535.27
Upside: +13.03%
Vertex Pharmaceuticals
Aug 3, 2026
Maintained: Buy
Price Target: $548 → $557
Current: $529.65
Upside: +5.16%
Spyre Therapeutics
Jul 28, 2026
Downgraded: Hold
Price Target: n/a
Current: $102.74
Upside: -
Ionis Pharmaceuticals
Jul 15, 2026
Downgraded: Hold
Price Target: n/a
Current: $55.42
Upside: -
Intellia Therapeutics
Jul 15, 2026
Downgraded: Sell
Price Target: $9
Current: $12.02
Upside: -25.12%
Sarepta Therapeutics
Jul 8, 2026
Upgraded: Buy
Price Target: $27
Current: $18.22
Upside: +48.19%
Celldex Therapeutics
Jun 14, 2026
Maintained: Buy
Price Target: $44
Current: $44.33
Upside: -0.74%
ABIVAX Société Anonyme
Jun 3, 2026
Rated: Buy
Price Target: $176 → $136
Current: $126.81
Upside: +7.25%
Vera Therapeutics
Jun 2, 2026
Maintained: Buy
Price Target: $88
Current: $30.29
Upside: +190.52%
Palisade Bio
Apr 8, 2026
Initiated Coverage: Buy
Price Target: $7
Current: $2.14
Upside: +227.10%
Apr 8, 2026
Initiated Coverage: Buy
Price Target: $48
Current: $19.47
Upside: +146.53%
Apr 8, 2026
Maintained: Buy
Price Target: $98
Current: $108.49
Upside: -9.67%
Apr 8, 2026
Initiated Coverage: Buy
Price Target: $42
Current: $34.42
Upside: +22.02%
Apr 6, 2026
Maintained: Buy
Price Target: $47
Current: $40.93
Upside: +14.83%
Mar 23, 2026
Upgraded: Buy
Price Target: $24
Current: $16.59
Upside: +44.67%
Jan 7, 2026
Initiated Coverage: Hold
Price Target: n/a
Current: $134.69
Upside: -
Jan 6, 2026
Downgraded: Hold
Price Target: n/a
Current: $109.62
Upside: -
Nov 24, 2025
Downgraded: Hold
Price Target: n/a
Current: $864.74
Upside: -
Nov 5, 2025
Initiated Coverage: Buy
Price Target: $13
Current: $4.72
Upside: +175.42%
Aug 14, 2025
Maintained: Buy
Price Target: $54 → $173
Current: $132.57
Upside: +30.50%
Aug 4, 2025
Upgraded: Hold
Price Target: n/a
Current: $221.20
Upside: n/a
Jun 16, 2025
Initiated Coverage: Buy
Price Target: $49
Current: $83.70
Upside: n/a
May 21, 2025
Reiterated: Buy
Price Target: $25
Current: $57.87
Upside: n/a
Mar 17, 2025
Maintained: Buy
Price Target: $84
Current: $121.07
Upside: n/a
Feb 3, 2025
Initiated Coverage: Buy
Price Target: $20
Current: $104.68
Upside: n/a
Feb 3, 2025
Initiated Coverage: Hold
Price Target: n/a
Current: $84.36
Upside: n/a
Feb 3, 2025
Initiated Coverage: Buy
Price Target: $19
Current: $32.44
Upside: n/a
Jun 10, 2024
Rated: Buy
Price Target: $29
Current: $22.97
Upside: n/a
Feb 14, 2024
Initiated Coverage: Hold
Price Target: n/a
Current: $54.07
Upside: n/a
Feb 14, 2024
Initiated Coverage: Buy
Price Target: n/a
Current: $35.25
Upside: n/a
Oct 25, 2023
Maintained: Buy
Price Target: $4
Current: $7.18
Upside: n/a
Aug 10, 2023
Reiterated: Buy
Price Target: $60
Current: $0.0001
Upside: n/a